PrecisionPhage Secures €2.2M Seed Funding
PrecisionPhage has raised €1M in investments from Nordic Science Investment, Genetricum, and Unifund. Additionally, PrecisionPhage has secured €1.2M in Deep Tech Accelerator funding from Business Finland. This Seed enables PrecisionPhage to position itself at the forefront of the phage industry - one of the fastest growing fields combating the pressing issue of antibiotic resistance.
Phages offer solutions against resistant bacteria
Antibiotic resistance is an escalating threat, as new antibiotics are not entering the market at a sufficient pace, and while bacterial resistance continues to increase. However, sustainable alternatives exist to combat bacterial infections. Rather than relying solely on conventional antibiotics, PrecisionPhage seeks to harness bacteria’s own predators – bacteriophages. In natural environments, phages limit bacterial population growth, and when used appropriately, they can perform the same role among pathogens.
PrecisionPhage aims to further the phage field on multiple fronts
PrecisionPhage takes a multifaceted approach to the emerging field of phage therapy: the company develops bioinformatic tools for phage analysis during research and production processes, offers phages for licensing against the most common drug-resistant pathogens, and provides high-quality laboratory services for phage isolation and R&D. The company works continuously with international partners to develop deep-tech solutions against antibiotic resistance and for biosafety, issues among humanity's most pressing problems. Now, the company's capabilities are elevated even higher with the newly secured funds.
